1. Home
  2. LWLG vs KROS Comparison

LWLG vs KROS Comparison

Compare LWLG & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightwave Logic Inc.

LWLG

Lightwave Logic Inc.

HOLD

Current Price

$3.86

Market Cap

578.6M

Sector

Industrials

ML Signal

HOLD

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

HOLD

Current Price

$18.58

Market Cap

655.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LWLG
KROS
Founded
1991
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
578.6M
655.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
LWLG
KROS
Price
$3.86
$18.58
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$22.20
AVG Volume (30 Days)
2.3M
564.7K
Earning Date
11-14-2025
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.57
Revenue
$100,605.00
$246,718,000.00
Revenue This Year
N/A
$6,924.79
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$11.30
Revenue Growth
N/A
37798.31
52 Week Low
$0.79
$9.12
52 Week High
$6.26
$22.55

Technical Indicators

Market Signals
Indicator
LWLG
KROS
Relative Strength Index (RSI) 54.26 42.98
Support Level $3.09 $17.51
Resistance Level $4.00 $21.76
Average True Range (ATR) 0.24 0.80
MACD 0.12 -0.50
Stochastic Oscillator 91.38 24.94

Price Performance

Historical Comparison
LWLG
KROS

About LWLG Lightwave Logic Inc.

Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: